Summary of Action

In 2020, several class-action lawsuits were filed against Reckitt Benckiser (RB) for falsely advertising the brain supplement Neuriva as “clinically proven” to improve several areas of cognitive functioning, including memory and focus, when, in reality, competent scientific evidence does not support, and even contradicts, these marketing claims. A February 2021 proposed settlement agreement seeks to resolve these lawsuits but provides no meaningful benefit to the class and allows RB to continue deceptively advertising Neuriva. For these reasons, filed a brief in July 2021 as amicus curiae opposing the proposed settlement agreement as unfair to consumers.

Print Friendly, PDF & Email

Tags: ,

Leave a Reply

Back to Top ↑